AVADEL PHARMACEUTICALS PLC(AVDL)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

AVADEL PHARMACEUTICALS PLC (AVDL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVDL at 56.7/100 on a 32-signal composite quality model, placing it at rank #1,059 of 2,856 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (Q3 2025), AVADEL PHARMACEUTICALS PLC reports quarterly revenue of $77.5M, net income of $20.0K, an operating margin of 2.5%. AVDL trades on the Nasdaq exchange and files with the SEC under CIK 1012477. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVDL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AVADEL PHARMACEUTICALS PLC directly from SEC EDGAR.

AI Quality Score

56.7/100

AI Rank

#1,059

Revenue

$77.5M

Net Income

$20.0K

Free Cash Flow

$22.2M

Operating Margin

2.5%

AVDL key financials by period

AVADEL PHARMACEUTICALS PLC reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202410-K$169.1M$-48.8M-25.1%
FY 202310-K$28.0M$-160.3M
FY 202010-K$22.3M$7.0M26.0%
FY 201910-K$59.2M$-33.2M-40.7%
FY 201810-K$103.3M$-95.3M-101.6%
FY 201710-K$173.2M$68.3M51.7%

Institutions holding AVDL

Institutional investors reporting a position in AVADEL PHARMACEUTICALS PLC on SEC Form 13F.
InstitutionSharesValueReported
HUNTINGTON NATIONAL BANK1$16.002026-06-30
AVDL

AVADEL PHARMACEUTICALS PLC

AVDL
NasdaqMid CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

56.7/100

Rank #1,059 of 2,856 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q3 2025
EDGAR

$77.47M

Net Income

Q3 2025
EDGAR

$20.0K

EPS (Diluted)

Q3 2025
EDGAR

$0.00

Operating Margin

Q3 2025
EDGAR

2.5%

ROIC

Q3 2025
EDGAR

7.9%

Free Cash Flow

Q3 2025
EDGAR

$22.20M

Top Institutional Holders

as of Q2 2026
$16 total

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…